Skip to main content

Advertisement

Table 2 RISH and marker screening results in all samples

From: Paving the way for more precise diagnosis of EcPV2-associated equine penile lesions

ID Diagnosis EcPV2 RISH p53 MCM7 Ki67
GS DNS b nb b nb b nb
1 SCC (G3) pos 2 3 2 4 3 1 1
2 SCC (G2) pos 4 4 3 4 2 0 0
3 SCC (G3) pos 7 4 2 4 2 2 1
4 early SCC (G3) pos 0 4 2 4 2 0 0
5 early SCC (G3) pos 3 4 3 4 3 3 1
6 CIS pos 1 4 3 4 3 3 2
7 CIS (pos) 0 4 3 4 2 2 1
8 CIS (pos) 0 2 2 4 3 2 2
9 Papilloma pos 27 4 1 4 3 1 1
10 Papilloma pos 0 4 1 4 2 3 1
11 Papilloma pos 69 4 2 4 4 3 2
12 Papilloma pos 8 4 1 4 2 2 1
13 Papilloma pos 14 4 1 4 3 2 1
14 Hyperplasia pos 98 2 1 4 1 1 1
15 Hyperplasia pos 72 3 1 4 2 2 1
16 Hyperplasia pos 27 2 1 4 2 2 1
17 Hyperplasia pos 84 2 1 4 2 3 1
18 Hyperplasia pos 7 4 1 4 2 2 1
19 Hyperplasia pos 49 4 2 4 1 2 1
9a normal adjacent skin neg 0 2 1 4 1 1 0
12a normal adjacent skin neg 0 3 2 4 1 1 1
14a normal adjacent skin neg 0 2 1 4 2 2 1
15a normal adjacent skin neg 0 3 2 4 1 2 1
16a normal adjacent skin neg 0 2 1 4 1 2 1
  1. Pos: positive; (pos): weak positive, neg: negative; b: basal layer; nb: non-basal layers; 0: negative; 1: < 10% of cells positive; 2: 10–50% of cells positive; 3: 51–90% of cells positive; 4: > 90% of cells positive